This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice
Rheumatology and Therapy Open Access 19 November 2021
-
Network pharmacology-based study on the mechanism of Yiganling capsule in hepatitis B treatment
BMC Complementary Medicine and Therapies Open Access 05 February 2020
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chyuan IT, Tsai HF, Tzeng HT, Sung CC, Wu CS, Chen PJ et al. Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model. Cell Mol Immunol. 2015; 12: 317–325.
Tzeng HT, Tsai HF, Chyuan IT, Liao HJ, Chen CJ, Chen PJ et al. Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model. PLoS One 2014; 9: e103008.
Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A. 2010; 107: 798–802.
Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005; 79: 9369–9380.
Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61: 1754–1764.
Durantel D, Zoulim F. Innate response to hepatitis B virus infection: observations challenging the concept of a stealth virus. Hepatology 2009; 50: 1692–1695.
Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001; 19: 65–91.
Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25–36.
Biermer M, Puro R, Schneider RJ. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol. 2003; 77: 4033–4042.
Ebert G, Preston S, Allison C, Cooney J, Toe JG, Stutz MD et al. Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. Proc Natl Acad Sci U S A. 2015; 112: 5797–5802.
Chisari FV. Cytotoxic T cells and viral hepatitis. The Journal of clinical investigation 1997; 99: 1472–1477.
Puro R, Schneider RJ. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol. 2007; 81: 7351–7362.
Park YK, Park ES, Kim DH, Ahn SH, Park SH, Lee AR et al. Cleaved c-FLIP mediates the antiviral effect of TNF-alpha against hepatitis B virus by dysregulating hepatocyte nuclear factors. J Hepatol. 2016; 64: 268–277.
Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hosel M et al. Interferon-gamma and Tumor Necrosis Factor-alpha Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis. Gastroenterology 2016; 150: 194–205.
Huang LR, Wohlleber D, Reisinger F, Jenne CN, Cheng RL, Abdullah Z et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nature immunology 2013; 14: 574–583.
Xiao Q, Fu B, Chen P, Liu ZZ, Wang W, Ye Q. Three polymorphisms of tumor necrosis factor-alpha and hepatitis B virus related hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2016; 95: e5609.
Ye H, Zhang XW, Mu R, Fang LK, Gu JR, Lin J et al. Anti-TNF therapy in patients with HBV infection—analysis of 87 patients with inflammatory arthritis. Clinical rheumatology 2014; 33: 119–123.
Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221–244 e223.
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487–501.
Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nature reviews Rheumatology 2016; 12: 49–62.
Acknowledgements
This work was financially supported by a grant from the Ministry of Science and Technology (MOST), Taiwan
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Chyuan, IT., Hsu, PN. Tumor necrosis factor: The key to hepatitis B viral clearance. Cell Mol Immunol 15, 731–733 (2018). https://doi.org/10.1038/cmi.2017.139
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cmi.2017.139
Keywords
This article is cited by
-
Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice
Rheumatology and Therapy (2022)
-
Network pharmacology-based study on the mechanism of Yiganling capsule in hepatitis B treatment
BMC Complementary Medicine and Therapies (2020)